Fragile X: New drug strategy corrects behavioral + biochemical measures in mouse model
Research in mice shows that a pharmacological strategy can alleviate multiple behavioral and cellular deficiencies in a mouse model of fragile X syndrome (FXS), the most common inherited form of intellectual disability and a major single-gene cause of autism spectrum disorders.
The results were published online Friday by Neuropsychopharmacology, and are being presented at the NFXF International Fragile X Conference in Cincinnati.
The paper represents a collaboration between three laboratories: two at Emory led by Gary Bassell, PhD, professor and chair of cell biology at Emory University School of Medicine, and Shannon Gourley, PhD (Gourley is based at Yerkes National Primate Research Center), and one at Cincinnati Children’s, led by Christina Gross, PhD. Dr. Bassell is a faculty member in the BCDB and NS programs and Dr. Gourley is a faculty member in the MSP and NS programs.
Click here to view the full story in the Emory News Center. The story was also featured in Lab Land - The Emory Health Sciences Research Blog and Technology Networks.